This study provides an opportunity to combine varenicline and bupropion SR and capitalize on
the potential additive benefit. The investigators hypothesize that this will further increase
long-term (≥ 6 months) smoking abstinence rates.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Cancer Institute (NCI) University of Minnesota University of Minnesota - Clinical and Translational Science Institute